Scilex Holding (SCLX) Amortization - Intangibles (2022 - 2026)
Scilex Holding (SCLX) posted quarterly Amortization - Intangibles of $2.1 million for Q1 2026, up 108.78% year-over-year from $1.0 million in Q1 2025, and up 56.82% on a QoQ basis from $1.3 million in Q4 2025.
Scilex Holding (SCLX) Amortization - Intangibles (2022 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Amortization - Intangibles for 5 consecutive years, with $2.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortization - Intangibles rose 108.78% year-over-year to $2.1 million; the TTM figure through Mar 2026 stood at $5.4 million (up 36.01% YoY), while the FY2025 annual figure was $4.4 million, up 8.26% from the prior year.
- Amortization - Intangibles came in at $2.1 million for Q1 2026 at Scilex Holding, up from $1.3 million in the prior quarter.
- The five-year high for Amortization - Intangibles was $2.1 million in Q1 2026, with the low at $935000.0 in Q1 2022.
- Average Amortization - Intangibles over 5 years is $1.1 million, with a median of $1.0 million recorded in 2022.
- Across the five-year window, Amortization - Intangibles decreased 2.53% in 2023 and jumped 108.78% in 2026, its largest moves.
- Year by year, Amortization - Intangibles stood at $1.0 million in 2022, then decreased by 0.0% to $1000000.0 in 2023, then grew by 0.1% to $1.0 million in 2024, then surged by 33.27% to $1.3 million in 2025, then surged by 56.82% to $2.1 million in 2026.
- According to Business Quant data, Amortization - Intangibles over the past three periods registered $2.1 million, $1.3 million, and $1.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.09 Mn |
| Dec 31, 2025 | 1.33 Mn |
| Sep 30, 2025 | 1.02 Mn |
| Jun 30, 2025 | 1.00 Mn |
| Mar 31, 2025 | 1.00 Mn |
| Dec 31, 2024 | 1.00 Mn |
| Sep 30, 2024 | 1.00 Mn |
| Jun 30, 2024 | 1.00 Mn |
| Mar 31, 2024 | 1.03 Mn |
| Dec 31, 2023 | 1,000,000.00 |
| Sep 30, 2023 | 1.00 Mn |
| Jun 30, 2023 | 1.00 Mn |
| Mar 31, 2023 | 1.00 Mn |
| Dec 31, 2022 | 1.00 Mn |
| Sep 30, 2022 | 1.03 Mn |
| Jun 30, 2022 | 935,000.00 |
| Mar 31, 2022 | 935,000.00 |